Auswahl der wissenschaftlichen Literatur zum Thema „Antibodies“

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Antibodies" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Antibodies"

1

Deora, Kanika, und Ruchee Khanna. „Clinical Profile of the Patients with Antiphospholipid Antibodies: Lupus Anticoagulant and Anticardiolipin Antibodies“. Indian Journal of Forensic Medicine and Pathology 12, Nr. 3 (2019): 195–99. http://dx.doi.org/10.21088/ijfmp.0974.3383.12319.6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Chiswell, David J., und John McCaffery. „Phage antibodies: will new ‘coliclonal’ antibodies replace monoclonal antibodies?“ Trends in Biotechnology 10 (1992): 80–84. http://dx.doi.org/10.1016/0167-7799(92)90178-x.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Linhardt, Robert J., C. W. Abell, R. M. Denney, B. W. Altrock, R. Auerbach, S. D. Bernal, R. E. Canfield et al. „Monoclonal antibodies and immobilized antibodies“. Applied Biochemistry and Biotechnology 15, Nr. 1 (Juni 1987): 53–80. http://dx.doi.org/10.1007/bf02798506.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Favoreel, Herman W., Geert Van Minnebruggen, Gerlinde R. Van de Walle, Jolanta Ficinska und Hans J. Nauwynck. „Herpesvirus interference with virus-specific antibodies: Bridging antibodies, internalizing antibodies, and hiding from antibodies“. Veterinary Microbiology 113, Nr. 3-4 (März 2006): 257–63. http://dx.doi.org/10.1016/j.vetmic.2005.11.003.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Clark, A. „Antibodies“. Journal of Clinical Pathology 42, Nr. 5 (01.05.1989): 559. http://dx.doi.org/10.1136/jcp.42.5.559-c.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Bradbury, Andrew, Nileena Velappan, Vittorio Verzillo, Milan Ovecka, Leslie Chasteen, Daniele Sblattero, Roberto Marzari, Jianlong Lou, Robert Siegel und Peter Pavlik. „Antibodies in proteomics I: generating antibodies“. Trends in Biotechnology 21, Nr. 6 (Juni 2003): 275–81. http://dx.doi.org/10.1016/s0167-7799(03)00112-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Kounis, Nicholas G., George D. Soufras und George N. Kounis. „Antibodies against antibodies inducing Kounis syndrome“. International Journal of Cardiology 168, Nr. 5 (Oktober 2013): 4804–5. http://dx.doi.org/10.1016/j.ijcard.2013.07.037.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Trier, Nicole, Paul Hansen und Gunnar Houen. „Peptides, Antibodies, Peptide Antibodies and More“. International Journal of Molecular Sciences 20, Nr. 24 (13.12.2019): 6289. http://dx.doi.org/10.3390/ijms20246289.

Der volle Inhalt der Quelle
Annotation:
The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively low success. Based on this, peptides, antibodies, and peptide antibodies have established their importance and remain crucial reagents in molecular biology.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Matraszek, Veronika Viktoria, Hynek Heřman und Ilona Hromadníková. „The relevance of antiphospholipid antibodies in obstetrics“. Česká gynekologie 89, Nr. 3 (22.06.2024): 237–44. http://dx.doi.org/10.48095/cccg2024237.

Der volle Inhalt der Quelle
Annotation:
Summary: Aim and methodology: To provide a comprehensive review on new findings and current recommendations regarding antiphospholipid antibodies with particular emphasis on clinical impact on gestation. Conclusion: Antiphospholipid antibodies are an important risk factor for the development of a series of pregnancy-related complications. Early diagnosis and appropriate therapy can reduce the incidence of pregnancy loss and pregnancy-related complications. Key words: antiphospholipid antibodies – antiphospholipid syndrome – lupus anticoagulant – anticardiolipin antibodies – anti-ß2-glycoprotein I antibodies
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Shoenfeld, Yehuda. „The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies“. Nature Medicine 10, Nr. 1 (Januar 2004): 17–18. http://dx.doi.org/10.1038/nm0104-17.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dissertationen zum Thema "Antibodies"

1

Ng, King Man. „Anti-neurofascin antibodies“. Diss., lmu, 2012. http://nbn-resolving.de/urn:nbn:de:bvb:19-150730.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Austin, Eric B. „Human monoclonal antibodies“. Thesis, University of Nottingham, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.276187.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Evans, Rachael Yvonne. „The production of anti-idiotopic antibodies to monoclonal anti-RhD antibodies“. Thesis, Lancaster University, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.274194.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Kang, Sun-ah. „Apoptotic Cells, Anti-Phospholipid Antibodies, and Anti-Chromatin Antibodies in Autoimmunity“. Diss., Temple University Libraries, 2008. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/15651.

Der volle Inhalt der Quelle
Annotation:
Microbiology and Immunology
Ph.D.
Antiphospholipid antibodies (APAs) are detected in various autoimmune diseases, such as antiphospholipid syndrome (APS) and systemic lupus erythematosus. In addition to their binding to negatively charged phospholipids, APAs often cross-react with other molecules. Their potential biological effects are not fully understood. Apoptotic cells are a potential source of auto-antigens during systemic autoimmunity. Inefficient clearance of apoptotic cells results in the development of autoimmune manifestations and intracellular antigens such as nucleosomes become accessible during apoptosis. We examined a panel of monoclonal APAs generated from NZW/BXSB F1, a strain which spontaneously develops autoimmune symptoms reminiscent of APS. These APAs did not bind to live cells, but reacted strongly with different structures within apoptotic cells. Further analysis with various inhibitors indicated that the binding of APAs to apoptotic cells depends on specific caspase activities and on the modification of auto-antigens by reactive oxygen species (ROS). Therefore, apoptotic cells provide a potential source of APA antigens that may not be limited to phospholipids. Our data also indicate that physical accessibility and apoptosis-specific modification of auto-antigens by caspases or ROS are crucial factors for APA-antigen interactions. Various auto-antibodies such as APAs and anti-chromatin antibodies are pathogenic outcome of chronic autoimmune diseases. Their binding to auto-antigens, presumably exposed on apoptotic cells, elicits subsequent amplification of inflammatory responses, thus worsening disease progression. However, the precise immunological functions of auto-antibodies and the mechanism behind are not fully comprehended yet. We investigated immune responses generated by four different auto-immune complexes (auto-ICs) composed of auto-antibodies and apoptotic cells. In the presence of TLR ligation, the presence of auto-antibodies in auto-ICs amplified immune responses generated by apoptotic cells. In most cases, almost all the auto-ICs tested suppressed IL12, TNFa, while increasing IL10 production from macrophages. Further studies with various anti-Fc?R antibodies implied the essential role of various Fc?Rs in elevation of IL10 by auto-ICs. Studies with Mer-/- macrophages indicated that Mer is also crucial in auto-IC mediated augmentation of IL10 production. However, Mer was dispensable for the suppression of IL12. Taken together, auto-antibodies, by forming immune complexes with apoptotic cells, perform strong immunomodulatory functions. Particular importance is in the role of Fc?Rs and Mer in anti-inflammatory responses generated by auto-ICs. Paradoxical, but indispensible contribution of TLR ligation, especially TLR4, in anti-inflammatory responses generated by auto-ICs suggests that auto-antibodies may work as another layer of defense against endogenous danger signals.
Temple University--Theses
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Chmura, A. J. „Rational engineering of antibodies with irreversible binding : antibodies with infinite affinity /“. Connect to Digital dissertations. Restricted to UC campuses. Access is free to UC campus dissertations, 2001. http://uclibs.org/PID/11984.

Der volle Inhalt der Quelle
Annotation:
Thesis (Ph. D.)--University of California, Davis, 2002.
Degree granted in Chemistry. Dissertation completed in 2001; degree granted in 2002. Also available via the World Wide Web. (Restricted to UC campuses).
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Rada-Briega, Cristina. „Somatic hypermutation of antibodies“. Thesis, University of Cambridge, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.318450.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Plumpton, Christopher. „Monoclonal antibodies against phytochrome“. Thesis, University of Cambridge, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.358677.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Bentall, Andrew John. „Antibodies in kidney transplantation“. Thesis, University of Birmingham, 2015. http://etheses.bham.ac.uk//id/eprint/5817/.

Der volle Inhalt der Quelle
Annotation:
The aim of this thesis is to examine the effect of anti-donor antibodies in the clinical management and outcomes of antibody incompatible kidney transplantation. Initial studies were conducted to improve measurement of anti-ABO specific blood group antibodies. The specificity of antibody binding to blood group antigens (BGA) depended upon the assay platform and the nature of the core structure to which the BGA was bound. A standardised haemagglutination assay had excellent reproducibility, which was then applied to the analysis of samples derived from a study of 100 ABO incompatible kidney transplantation (ABOiKTx) in the UK where good clinical outcomes were achieved but there was wide variation reported in local assays quantifying BGA specific antibodies, without survival differences. In a highly sensitised HLA incompatible kidney transplant recipients (HLAiKTx), I demonstrated long term outcomes were poor compared to a compatible cohort, in particular with pre-formed donor specific anti-HLA Class II antibodies, in which histological injury of antibody damage occurred significantly earlier than with Class I antibodies. Further studies demonstrated that anti-HLA antibodies were associated with an inflammatory phenotype, but anti-donor ABO specific antibodies did not despite the activation of complement. Thus, inhibiting terminal complement activation, whilst reducing early antibody-mediated rejection did not abrogate all inflammation which was associated with the presence of IgM DSA. Reproducible and standardised assays are needed for antibody assessment in order to make good clinical decisions to improve patient outcomes. Further studies are needed to stop production or block mechanisms of ongoing cellular infiltrate to improve patient outcomes.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Alcocer, Marcos J. C. „Wheat peptides and antibodies“. Thesis, University of East Anglia, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.306066.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Farzad, Zohreh (Emami Aleagha). „Studies on anti-tetanus antibodies“. Thesis, University of Edinburgh, 1985. http://hdl.handle.net/1842/23886.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bücher zum Thema "Antibodies"

1

Szentivanyi, Andor, Paul H. Maurer und Bernard W. Janicki, Hrsg. Antibodies. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Subramanian, G., Hrsg. Antibodies. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-8875-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Subramanian, G., Hrsg. Antibodies. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-8877-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Anderson, Kevin J. Antibodies. New York: HarperPrism, 1998.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Anderson, Kevin J. Antibodies. New York, N.Y: HarperPrism, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Anderson, Kevin J. Antibodies. New York: HarperCollins, 2008.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Anderson, Kevin J. Antibodies. London: HarperCollins, 1997.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

1935-, Subramanian G., Hrsg. Antibodies. New York: Kluwer Academic/Plenum Publishers, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

1935-, Subramanian G., Hrsg. Antibodies. New York: Kluwer Academic/Plenum Publishers, 2004.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Skal, David J. Antibodies. New York: Congdon & Weed, 1988.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Buchteile zum Thema "Antibodies"

1

Dorrington, Keith J., und Michel H. Klein. „The Three-Dimensional Structure of Immunoglobulin G and its Relationship to the Expression of Biological Functions“. In Antibodies, 3–10. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Siskind, Gregory W., Edmond A. Goidl, Young Tai Kim, Marc E. Weksler und G. Jeanette Thorbecke. „Anti-Hapten Idiotype Models in Studies of Aging and Idiotype Networks“. In Antibodies, 107–15. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_10.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Erlanger, B. F., W. L. Cleveland, N. H. Wasserman, H. H. Ku, B. L. Hill, R. Sarangarajan, R. Rajagopalan et al. „Antibodies to Acetylcholine, Adenosine and Glucocorticoid Receptors by an Auto-Anti-Idiotypic Route“. In Antibodies, 119–34. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Geha, Raif S. „Idiotypic Interactions in the Treatment of Human Diseases“. In Antibodies, 135–53. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_12.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Talal, Norman. „Regulation of Autoimmune Diseases“. In Antibodies, 155–63. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_13.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Morrison, Sherie L., Letitia A. Wims, Polly D. Gregor, Barry J. Kobrin und Vernon T. Oi. „Transfectomas Provide Antibodies with Novel Structures and Functions“. In Antibodies, 167–78. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_14.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Uhr, Jonathan W., R. Jerrold Fulton und Ellen S. Vitetta. „The Use of Ricin a Chain-Containing Immunotoxins to Kill Neoplastic B Cells“. In Antibodies, 179–87. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_15.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Oldham, Robert K. „Monoclonal Antibodies and Immunoconjugates as Anti-Cancer Agents“. In Antibodies, 189–200. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_16.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Siskind, Gregory W. „Overview and Comments“. In Antibodies, 203–6. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_17.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Kohler, Heinz, und Thomas Kieber-Emmons. „New Concepts in Antibody Structure“. In Antibodies, 11–17. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-1873-6_2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Antibodies"

1

NERI, DARIO. „FROM INTACT ANTIBODIES TO ARMED ANTIBODIES“. In 23rd International Solvay Conference on Chemistry. WORLD SCIENTIFIC, 2014. http://dx.doi.org/10.1142/9789814603836_0036.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Kiefel, V., S. Santoso und C. Mueller-Eckhardt. „ANALYSIS OF PLATELET REACTIVE ANTIBODIES USING MONOCLONAL ANTIBODIES“. In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643929.

Der volle Inhalt der Quelle
Annotation:
The characterization of platelet reactive alloantibodies and autoantibodies is mandatory for the diagnosis of posttransfusion purpura, neonatal alloimmune thrombocytopenia, autoimmune thrombocytopenia and for the selection of platelet donors prior to platelet transfusions in immunized polytransfused patients. The platelet immunofluorescence test is suitable for the detection of platelet reactive antibodies. In many cases, however, mixtures containing different platelet reactive antibodies have to be dissected.In order to analyze these sera, we have developed a novel enzyme immunoassay based upon monoclonal antibody specific immobilization of platelet antigens (MAIPA). In brief, platelets are incubated simultaneously with the (human) serum to be investigated and a monoclonal (mouse) antibody directed against an epitope on the same platelet membrane glycoprotein (GP). Platelets are then washed and solubilized in TRIS buffered saline containing NP40. The lysed platelets are then pipetted into the wells of microtiter plates, coated with goat anti mouse IgG where mouse anti GP-complexes are immobilized. Human platelet reactive antibodies on the same GP are detected using enzyme labelled goat anti human IgG, IgM, or IgA, respectively. Using mab Gi5, mab FMC25, mab w6.32 directed against epitopes on the glycoprotein complex IIb/IIIa, glycoprotein Ib and HLA class I molecule, respectively, and a panel of typed platelet donors, even sera containing different platelet reactive antibodies are readily analyzed. Results of experiments with platelet specific alloantibodies (anti P1A1, anti P1A2 and anti Bak(a)), autoantibodies (against the GP Ilb/IIIa complex and GP Ib) and a drug dependent antibody show that this assay allows to discriminate all these different platelet reactive antibodies.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Bundell, C., und P. Hollingsworth. „359 Antinuclear antibodies in iu/ml predicts dsdna and ena antibodies“. In LUPUS 2017 & ACA 2017, (12th International Congress on SLE &, 7th Asian Congress on Autoimmunity). Lupus Foundation of America, 2017. http://dx.doi.org/10.1136/lupus-2017-000215.359.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Zanlorenzi, Laís, Nelzi Ferreira de Queiroz Junior, Carlos Gomes Bezerra Sobrinh, Laura Vilas Boas, Renato Nishiara und Thelma Skare. „ANTINUCLEAR ANTIBODIES IN ENDOMETRIOSIS“. In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.2009.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

ESHHAR, ZELIG. „GENETICALLY ENGINEERED THERAPEUTIC ANTIBODIES“. In International Seminar on Nuclear War and Planetary Emergencies 25th Session. Singapore: World Scientific Publishing Co. Pte. Ltd., 2001. http://dx.doi.org/10.1142/9789812797001_0062.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

SIROTA, PINKHAS, KLARA SCHILD, MICHAEL FIRER, NEOMI ZURGIL, YORAM BARAK, AVNER ELIZUR und HANOCH SLOR. „ANTI Sm ANTIBODIES IN SCHIZOPHRENIA“. In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0014.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Ivanova, SM, GG Karpova, NV Bogachiova, TA Riazantctva und AI Speranskey. „THU0061 Ribosomal p protein antibodies“. In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.905.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Sun, Yanjie, Zhuoyun Wan und Zixiao Zhang. „Therapeutic Monoclonal Antibodies: Clinical Applications“. In International Conference on Biotechnology and Biomedicine. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0012020800003633.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Cucnik, Sasa. „SP0176 PATHOGENIC ANTIBODIES IN PHOSPHOLIPID SYNDROM“. In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8453.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

SIDHU, SACHDEV S. „FROM NATURAL ANTIBODIES TO SYNTHETIC PROTEINS“. In 23rd International Solvay Conference on Chemistry. WORLD SCIENTIFIC, 2014. http://dx.doi.org/10.1142/9789814603836_0035.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Antibodies"

1

Benkovic, Stephen J. Catalytic Antibodies. Fort Belvoir, VA: Defense Technical Information Center, März 1992. http://dx.doi.org/10.21236/ada252019.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ivy, John M. Production of Anti-Ferret IgA Antibodies; and production of monoclonal antibodies. Fort Belvoir, VA: Defense Technical Information Center, April 1994. http://dx.doi.org/10.21236/ada279534.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Bradley, David Sherman. Avian Diagnostic and Therapeutic Antibodies. Office of Scientific and Technical Information (OSTI), Dezember 2012. http://dx.doi.org/10.2172/1114116.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Snyder, Christopher M., und Lawrence J. Wysocki. Dissecting Immunogenicity of Monoclonal Antibodies. Fort Belvoir, VA: Defense Technical Information Center, Juni 2002. http://dx.doi.org/10.21236/ada407659.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Snyder, Christopher M., und Lawrence J. Wysocki. Dissecting Immunogenicity of Monoclonal Antibodies. Fort Belvoir, VA: Defense Technical Information Center, Juni 2003. http://dx.doi.org/10.21236/ada417364.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Jaszczak, R. J. SPECT assay of radiolabeled monoclonal antibodies. Office of Scientific and Technical Information (OSTI), Februar 1992. http://dx.doi.org/10.2172/7197646.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Jaszczak, R. J. SPECT assay of radiolabeled monoclonal antibodies. Office of Scientific and Technical Information (OSTI), Februar 1992. http://dx.doi.org/10.2172/7288347.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Borgford, Thor. Human-based Polyclonal Antibodies to Ricin. Fort Belvoir, VA: Defense Technical Information Center, Mai 2010. http://dx.doi.org/10.21236/ada533217.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Clynes, Raphael. Cytotoxic Mechanisms of Tumor Specific Antibodies. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2002. http://dx.doi.org/10.21236/ada411736.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Clynes, Raphael. Cytotoxic Mechanisms of Tumor Specific Antibodies. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2000. http://dx.doi.org/10.21236/ada392896.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie